Assessment of metabolic bariatric surgery for the remisson of obesity and type 2 diabetes

Objectives The aim of this study was to assess the short-term remission of both obesity and type 2 diabetes (T2D) after metabolic bariatric surgery (MBS). Background The prevalence of obesity is increasing at a rapid rate internationally, paralleled with an increase in the number of people with T2D. Bariatric surgery may induce a lot of anatomical, physiologic, and hormonal changes that improve diabetes with obesity, with durable effects. Patients and methods This study includes 20 obese diabetic patients who underwent MBS treatment of obesity and T2D. Surgical outcome, weight loss, glycated hemoglobin level, comorbidities, and complications were recorded. Patients were followed up every week for 1 month, and then on every month of the first year. All patients were followed up for at least 1 year. Results In the studies, the mean age was 40.08 ± 2 years, male/female ratio was 8/12, and mean BMI was 35.3. The mean operative time and estimated blood loss of sleeve gastrectomy are significantly less than Roux-en-Y gastric bypass. After surgery, mean BMI and mean glycated hemoglobin was reduced, with significant weight reduction (P Conclusion MBS is an effective procedure for treating morbid obesity and T2D which results in sustained weight loss and a high resolution of comorbidities.